Who Paid My Doc
Marynoll De La Paz
Hematology & Oncology Ponce, PR Medical Doctor
NPI 1740414291 CMS profile 1067851
2225 Ponce Byp Ste 607, Ste 101, Ponce, PR 00717
General payments
$18,187
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Marynoll De La Paz of Ponce, PR is reported in the CMS Open Payments database as having received $18,187 across 798 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 79th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,183 | 139 | |
| 2024 | General | $4,195 | 172 | |
| 2023 | General | $2,772 | 121 | |
| 2022 | General | $3,019 | 123 | |
| 2021 | General | $2,254 | 106 | |
| 2020 | General | $1,498 | 73 | |
| 2019 | General | $1,266 | 64 |
Beside peers
- Marynoll De La Paz
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Marynoll De La Paz were reported at $3,183. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Marynoll De La Paz | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,266 | $529 | $121–$2,516 | $163 |
| 2020 | $1,498 | $339 | $82–$2,213 | $114 |
| 2021 | $2,254 | $263 | $49–$1,965 | $132 |
| 2022 | $3,019 | $416 | $103–$2,395 | $149 |
| 2023 | $2,772 | $542 | $125–$2,646 | $160 |
| 2024 | $4,195 | $692 | $141–$3,008 | $164 |
| 2025 | $3,183 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 73 drugsPart D claims
3,561
Drug cost
$6,290,240
Branded share of claims
17.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 91 | $1,712,317 | |
| Ibrance Palbociclib | Brand | 86 | $1,370,294 | |
| Kisqali Ribociclib Succinate | Brand | 40 | $699,609 | |
| Venclexta Venetoclax | Brand | 37 | $575,523 | |
| Lenvima Lenvatinib Mesylate | Brand | 11 | $543,809 | |
| Verzenio Abemaciclib | Brand | 34 | $515,527 | |
| Nubeqa Darolutamide | Brand | 19 | $269,262 | |
| Xtandi Enzalutamide | Brand | 17 | $245,656 | |
| Reblozyl Luspatercept-Aamt | Brand | 17 | $168,116 | |
| Prolia Denosumab | Brand | 36 | $62,409 |
The 10 drugs with the highest cost, of 73 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 69 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| KEYTRUDA |
|
$331 | — | — |
| REBLOZYL |
|
$242 | 17 | — |
| IMFINZI |
|
$240 | — | — |
| OPDIVO |
|
$226 | — | — |
| VERZENIO |
|
$169 | 34 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 69 with PatronRecords
798 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Puerto Rico
Alexis Cruz Chacon
Hematology & Oncology · San Juan, PR
Jose Lozada Costas
Hematology & Oncology · San Juan, PR
Cristian Rodriguez Arocho
Hematology & Oncology · San Juan, PR
Noridza Rivera Rodriguez
Hematology & Oncology · San Juan, PR
Joel Lopez-Figueroa
Hematology & Oncology · Humacao, PR
Mirelis Acosta
Hematology & Oncology · San Juan, PR
Related records
Hematology & Oncology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.